Supernus to Host First Quarter 2014 Earnings Conference Call
April 29 2014 - 7:30AM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company expects to report the quarter
ending March 31, 2014 financial results after the close of the U.S.
financial markets Monday, May 12, 2014.
Jack Khattar, President and Chief Executive Officer and Greg
Patrick, Chief Financial Officer will host a conference call to
discuss first quarter 2014 financial results on Tuesday, May 13,
2014 at 9:00 AM Eastern Time.
A live webcast will be available at www.supernus.com. Following
the live call, a replay will be available on the Company's website
under 'Investor Info'. The webcast will be archived on the
Company's website for 30 business days following the live call.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference dial-in: |
877-288-1043 |
International dial-in: |
970-315-0267 |
Conference ID: |
35887259 |
Conference Call Name: |
Supernus Pharmaceuticals 1Q 2014 Earnings
Conference Call |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
CONTACT: Supernus Pharmaceuticals, Inc., 301-838-2591
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
or
Investor Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024